◀ Back to MAPK11
MAP2K3 — MAPK11
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
MAPK11
→
MAP2K3
(increases, MAP2K3 Activity, MAPK11 Activity)
Zhao et al., Mol Cell Biol 1999
Evidence: Following the initial description of p38 (p38a), three additional isoforms of this MAP kinase group have been cloned and characterized: p38b (18), p38g (also termed ERK6 or SAPK3) (22, 24, 30), and p38d (also termed SAPK4) (4, 17, 41). Two MAP kinase kinases (MKK), MKK3 and MKK6, are the upstream activators of the p38 group MAP kinases (6, 12, 14, 37).
-
BioCarta nfkb activation by nontypeable hemophilus influenzae:
MEK3 (MAP2K3)
→
MAPK11
(modification, activates)
-
KEGG Toll-like receptor signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, phosphorylation)
-
KEGG Fc epsilon RI signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG GnRH signaling pathway:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG Amyotrophic lateral sclerosis (ALS):
MAP2K3
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG MAPK signaling pathway:
MAP2K3
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, phosphorylation)
-
KEGG Toxoplasmosis:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
KEGG Influenza A:
MAP2K3/MAP2K6
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, activation)
-
NCI Pathway Database Regulation of p38-alpha and p38-beta:
p38alpha-beta (MAPK14/MAPK11)
→
RAC1/OSM/MEKK3/MKK3 complex (CCM2-MAP3K3-RAC1-MAP2K3)
(modification, collaborate)
Uhlik et al., Nat Cell Biol 2003
Evidence: mutant phenotype, other species
-
NCI Pathway Database CXCR3-mediated signaling events:
p38alpha-beta (MAPK14/MAPK11)
→
MKK3-MKK6-active (MAP2K3/MAP2K6)
(modification, collaborate)
Petrai et al., Int J Biochem Cell Biol 2008
Evidence: assay
-
Reactome Reaction:
MAPK11
→
MAP2K3
(reaction)
New et al., Mol Biol Cell 2003*, Sun et al., Cell 2007, Raingeaud et al., J Biol Chem 1995, Raingeaud et al., Mol Cell Biol 1996, New et al., EMBO J 1998
-
WikiPathways Structural Pathway of Interleukin 1 (IL-1):
MAP2K3
→
MAPK11
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
STRING interaction:
MAPK11
—
MAP2K3
(interaction, mapped from grid kegg_pathways mint intact)
-
STRING interaction:
MAP2K3
—
MAPK11
(interaction, mapped from grid)
Text-mined interactions from Literome
Martel-Pelletier et al., Arthritis Rheum 1999
(Osteoarthritis) :
Within minutes, IL-17 induced the phosphorylation of
mitogen activated protein kinase kinase-1/2 ( MEK-1/2 ), -3/6 ( MKK-3/6 ), p44/42, p38, and inhibitor of nuclear factor kappaB ( I kappaB)-alpha, as well as the
activation of
mitogen activated protein kinase activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 )
Tu et al., J Biomed Sci 2001
(Carcinoma, Hepatocellular) :
On the other hand, PD98059, a specific inhibitor of
mitogen activated protein kinase kinase ,
blocks TPA induced
MAPK activation but has no effect on TPA induced tyrosine phosphorylation
Huang et al., Biochem Biophys Res Commun 2003
:
MAP3Ks are components of a three tiered protein kinase pathway in which a MAP3K phosphorylates and activates a
mitogen activated protein kinase kinase ( MAP2K ), which in turn
activates a
mitogen activated protein kinase ( MAPK )
Wu et al., Free Radic Biol Med 2010
(Drug-Induced Liver Injury) :
This was followed by
activation of
MKK3/MKK6 and MKK4/MKK7 at 4-8 or 12h and then JNK/p38
MAPK at 8 to 12h
Huwiler et al., Br J Pharmacol 1994
:
2. Both nucleotides stimulate phosphorylation and
activation of
mitogen activated protein kinase and a biphasic phosphorylation of the up-stream
mitogen activated protein kinase kinase
Daum et al., FEBS Lett 1998
:
Pervanadate inhibits
mitogen activated protein kinase kinase-1 in a
p38MAPK dependent manner